^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
simmitinib (SYHA1817)
i
Other names: SYHA1817, SOMCL-15-290, SYHA 1817, SYHA-1817
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CSPC Pharma
Drug class:
FGFR inhibitor, VEGFR-2 inhibitor, CSF-1R inhibitor
Related drugs:
8d
An open-label and multicenter Phase Ⅰ Clinical Study to Evaluate the Safety and Efficacy of SYS6010 in combination with Enlonstobart and Simmitinib in patients with advanced esophageal cancer (ChiCTR2400089300)
P1, N=60, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology; The First Affiliated Hospital of Henan University of Science and Technolo
New P1 trial • Combination therapy • Metastases
|
Enshuxing (enlonstobart) • simmitinib (SYHA1817)
25d
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P3, N=450, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
New P3 trial
|
docetaxel • irinotecan • simmitinib (SYHA1817)
3ms
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
P1/2, N=252, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
New P1/2 trial
|
paclitaxel • trastuzumab envedotin (DP303c) • simmitinib (SYHA1817)
4ms
A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=138, Recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
New P2 trial • Metastases
|
simmitinib (SYHA1817)
1year
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=168, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
New P1/2 trial • Metastases
|
simmitinib (SYHA1817)
over2years
A Phase I Trial of Simmitinib in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Jan 2023
Enrollment open • Trial completion date • Trial primary completion date
|
VEGFA (Vascular endothelial growth factor A)
|
simmitinib (SYHA1817)
over2years
Development and validation of a high performance liquid chromatography-MS/MS method for determination of SOMCL-15-290 in a first-in-human study. (PubMed, Bioanalysis)
Quantification of SOMCL-15-290 was operated on an Xevo-TQS triple quadrupole tandem mass spectrometer in electrospray ionization positive mode. Results & The validated determination method of SOMCL-15-290 has proved feasible and was successfully utilized in the first-in-human study of SOMCL-15-290 in advanced solid tumor patients.
P1 data • Journal
|
KDR (Kinase insert domain receptor) • CSF1R (Colony stimulating factor 1 receptor)
|
simmitinib (SYHA1817)
Share via
